Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma - The Dana-Farber experience and meta-analysis of the literature

被引:266
作者
Gupta, Sheela G.
Wang, Linda C.
Penas, Pablo F.
Gellenthin, Martina
Lee, Stephanie J.
Nghiem, Paul
机构
[1] Dana Farber Brigham & Womens Canc Ctr, Cutaneous Oncol Dis Ctr, Boston, MA USA
[2] Dana Farber Brigham & Womens Canc Ctr, Ctr Outcomes & Policy Res, Boston, MA USA
[3] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA
[4] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA
[5] Hosp Univ Princesa, Dept Dermatol, Madrid, Spain
[6] Charite Univ Med, Dept Dermatol, Allergy & Skin Canc Ctr, Berlin, Germany
关键词
D O I
10.1001/archderm.142.6.685
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Objective: To determine the diagnostic accuracy and usefulness of sentinel lymph node biopsy (SLNB) and computed tomographic scans in the initial evaluation and treatment of patients with Merkel cell carcinoma (MCC). Design: Single-institution case series and literature based case-level meta-analysis. Setting: Academic cutaneous oncology clinic. Patients: Sixty-one adults with biopsy-proven MCC (30 who had undergone SLNB) plus 92 cases from the literature of patients who had undergone SLNB. Main Outcome Measures: Relapse-free survival Results: In 122 patients with no nodal disease found by physical examination, SLNB findings revealed nodal involvement in 39 cases (32%). At 3 years, the recurrence rate for those with a positive SLNB was 3 times (60%) higher than for those with a negative SLNB (20%; P =.03). Patients with a positive SLNB who received adjuvant nodal therapy had a relapse-free survival rate of 51% at 3 years (n = 26) compared with 0% for patients who did not receive nodal therapy (n = 3; P<.01). In contrast, among patients with a negative SLNB there was no significant difference in 3-year relapse-free survival rates for those who did (90%; n = 24) or did not (70%; n = 19; P =. 26) receive adjuvant nodal therapy. Using SLNB plus clinical follow-up as a gold standard, computed tomographic scans had low sensitivity (20%) for detecting MCC that had spread to the lymph node basin and low specificity for distant disease (only 4 of 21 "positive" scans were confirmed during 6 months of follow-up). Conclusions: Sentinel lymph node biopsy detects MCC spread in one third of patients whose tumors would have otherwise been clinically and radiologically understaged and who may not have received treatment to the involved node bed. There was a significant benefit of adjuvant nodal therapy, but only when the SLNB was positive. Thus, SLNB is important for both prognosis and therapy and should be performed routinely for patients with MCC. In contrast, computed tomographic scans have poor sensitivity in detecting nodal disease as well as poor specificity in detecting distant disease.
引用
收藏
页码:685 / 690
页数:6
相关论文
共 32 条
[1]   Epidemiology of primary Merkel cell carcinoma in the United States [J].
Agelli, M ;
Clegg, LX .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 49 (05) :832-841
[2]   The application of sentinel node radiolocalization to solid tumors of the head and neck: A 10-year experience [J].
Alex, JC .
LARYNGOSCOPE, 2004, 114 (01) :2-19
[3]   Surgical management of Merkel cell carcinoma [J].
Allen, PJ ;
Zhang, ZF ;
Colt, DC .
ANNALS OF SURGERY, 1999, 229 (01) :97-105
[4]  
Allen PJ, 2001, CANCER, V92, P1650, DOI 10.1002/1097-0142(20010915)92:6<1650::AID-CNCR1491>3.0.CO
[5]  
2-8
[6]   Merkel cell carcinoma: Prognosis and treatment of patients from a single institution [J].
Allen, PJ ;
Bowne, WB ;
Jaques, DP ;
Brennan, MF ;
Busam, K ;
Coit, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2300-2309
[7]  
Ames SE, 1998, J SURG ONCOL, V67, P251, DOI 10.1002/(SICI)1096-9098(199804)67:4<251::AID-JSO8>3.0.CO
[8]  
2-7
[9]  
Bilchik AJ, 1998, CANCER J SCI AM, V4, P351
[10]   Prognostic and therapeutic implications of sentinel lymphonodectomy and S-staging in Merkel cell carcinoma [J].
Düker, I ;
Starz, H ;
Bachter, D ;
Balda, BR .
DERMATOLOGY, 2001, 202 (03) :225-229